173 related articles for article (PubMed ID: 8632676)
61. Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine.
Momparler RL; Bouffard DY; Momparler LF; Marquet J; Zittoun J; Marie JP; Zittoun R
Int J Cancer; 1991 Oct; 49(4):573-6. PubMed ID: 1917159
[TBL] [Abstract][Full Text] [Related]
62. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
[TBL] [Abstract][Full Text] [Related]
63. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
64. Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
Liang A; Zhang H; Fang Y; Li Y; Zhu D; Chen F; Lu H; Fu J; Bo L
Pharmazie; 2012 Jul; 67(7):635-8. PubMed ID: 22888522
[TBL] [Abstract][Full Text] [Related]
65. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
[TBL] [Abstract][Full Text] [Related]
66. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis.
Grégoire V; Beauduin M; Bruniaux M; De Coster B; Octave Prignot M; Scalliet P
Int J Radiat Biol; 1998 May; 73(5):511-20. PubMed ID: 9652808
[TBL] [Abstract][Full Text] [Related]
67. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.
Bhalla K; MacLaughlin W; Cole J; Arlin Z; Baker M; Graham G; Grant S
Blood; 1987 Aug; 70(2):568-71. PubMed ID: 3607288
[TBL] [Abstract][Full Text] [Related]
68. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Löfgren C; Albertioni F; Paul C
Ther Drug Monit; 2005 Oct; 27(5):641-6. PubMed ID: 16175139
[TBL] [Abstract][Full Text] [Related]
69. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Kemena A; Gandhi V; Shewach DS; Keating M; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(3):193-9. PubMed ID: 1464155
[TBL] [Abstract][Full Text] [Related]
71. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
[TBL] [Abstract][Full Text] [Related]
72. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
73. Resistance of human leukemic cell lines to 1-beta-D-arabinofuranosylcytosine: characterization of an experimental model.
Gariboldi MB; Ravizza R; Marras E; Perletti G; De Simone A; Piccinini F; Monti E
Int J Oncol; 2001 Jun; 18(6):1245-9. PubMed ID: 11351258
[TBL] [Abstract][Full Text] [Related]
74. Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
Vrana JA; Rao AS; Wang Z; Jarvis WD; Grant S
Int J Oncol; 1998 Apr; 12(4):927-34. PubMed ID: 9499457
[TBL] [Abstract][Full Text] [Related]
75. The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells.
Berkovic D; Fleer EA; Breass J; Pförtner J; Schleyer E; Hiddemann W
Leukemia; 1997 Dec; 11(12):2079-86. PubMed ID: 9447824
[TBL] [Abstract][Full Text] [Related]
76. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
77. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Gandhi V; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
[TBL] [Abstract][Full Text] [Related]
78. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
79. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
[TBL] [Abstract][Full Text] [Related]
80. Delayed addition of deoxycytidine protects normal CD34+ cells against cytotoxicity of gemcitabine without compromising its activity against human leukemic cells.
Tiefenthaler M; Hohla F; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
Stem Cells; 2003; 21(3):266-71. PubMed ID: 12743321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
